DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Geyer jr. CE, Huang C-S, Mano MS. et al.
Phase III study of trastuzumab emtansine (T-DM1) vs. trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE.
SABCS 2018; Abstract GS1-10
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.